While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Lone Pine Capital’s Q1 2025 13F portfolio value dropped to $11.58B, with holdings reduced from 30 to 22, focusing on top tech ...

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

The stock's fall snapped a four-day winning streak.

Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Macquarie Asset Management, an investment management company, released its “Macquarie Large Cap Growth Fund” first quarter ...

Review Eli Lilly and Co (LLY:XNYS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Review the current Eli Lilly and Co (LLY:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if LLY is the best investment for you.

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...